Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition by Sciacovelli, M et al.
Page 1 of 29 
Fumarate is an epigenetic modifier that elicits epithelial-to-1 
mesenchymal transition 2 
Marco Sciacovelli1, Emanuel Gonçalves2, Timothy Isaac Johnson1, Vincent Roberto Zecchini1, 3 
Ana Sofia Henriques da Costa1, Edoardo Gaude1, Alizee Vercauteren Drubbel1, Sebastian 4 
Julian Theobald1, Sandra Abbo1, Maxine Tran3, Vinothini Rajeeve4, Simone Cardaci5, Sarah 5 
Foster6, Haiyang Yun7, Pedro Cutillas4, Anne Warren8, Vincent Gnanapragasam9, Eyal 6 
Gottlieb5, Kristian Franze6, Brian Huntly7, Eamonn Richard Maher10, Patrick Henry 7 
Maxwell11, Julio Saez-Rodriguez2,12 & Christian Frezza1 8 
1Medical Research Council Cancer Unit, University of Cambridge, CB2 0XZ, Cambridge, UK; 9 
2European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute (EBI), CB10 10 
1SD, Cambridge, UK; 3Department of Oncology, Uro-Oncology Research Group, University of 11 
Cambridge, CB2 0Ql, Cambridge, UK; 4Integrative Cell Signalling and Proteomics, Centre for 12 
Haemato-Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of 13 
London, Charterhouse Square, EC1M 6BQ, London, UK; 5Cancer Research UK Beatson Institute, 14 
G61 1BD, Glasgow, UK; 6Department of Physiology, Development and Neuroscience, University of 15 
Cambridge, Cambridge, UK; 7Department of Haematology, Cambridge Institute for Medical 16 
Research and Addenbrooke’s Hospital, and Wellcome Trust-Medical Research Council Cambridge 17 
Stem Cell Institute, University of Cambridge, CB2 0XY, Cambridge, UK; 8Department of Pathology, 18 
University of Cambridge, CB2 1QP, Cambridge, UK ;9Academic Urology Group, Department of 19 
Surgery, University of Cambridge, CB2 0QQ, Cambridge, UK; 10Department of Medical Genetics, 20 
University of Cambridge, CB2 0QQ, Cambridge, UK and NIHR Cambridge Biomedical Research 21 
Centre; 11Cambridge Institute for Medical Research, University of Cambridge, CB2 0XY, Cambridge, 22 
UK; 12RWTH Aachen University, Faculty of Medicine, Joint Research Center for Computational 23 
Biomedicine, Aachen 52074, Germany  24 
Page 2 of 29 
Mutations of the tricarboxylic acid cycle (TCA cycle) enzyme fumarate hydratase (FH) 25 
cause Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)1. FH-deficient renal 26 
cancers are highly aggressive and metastasise even when small, leading to an abysmal 27 
clinical outcome2. Fumarate, a small molecule metabolite that accumulates in FH-28 
deficient cells, plays a key role in cell transformation, making it a bona fide 29 
oncometabolite3. Fumarate was shown to inhibit α-ketoglutarate (aKG)-dependent 30 
dioxygenases involved in DNA and histone demethylation4,5. However, the link between 31 
fumarate accumulation, epigenetic changes, and tumorigenesis is unclear. Here we show 32 
that loss of FH and the subsequent accumulation of fumarate elicits an epithelial-to-33 
mesenchymal-transition (EMT), a phenotypic switch associated with cancer initiation, 34 
invasion, and metastasis6. We demonstrate that fumarate inhibits Tet-mediated 35 
demethylation of a regulatory region of the antimetastatic miRNA cluster6 miR-200ba429, 36 
leading to the expression of EMT-related transcription factors and enhanced migratory 37 
properties. These epigenetic and phenotypic changes are recapitulated by the incubation 38 
of FH-proficient cells with cell-permeable fumarate. Loss of FH is associated with 39 
suppression of miR-200 and EMT signature in renal cancer patients, and is associated 40 
with poor clinical outcome. These results imply that loss of FH and fumarate 41 
accumulation contribute to the aggressive features of FH-deficient tumours.  42 
To identify oncogenic features associated with FH loss we performed unbiased proteomics 43 
analyses of mouse (Fh1-/-) and human (UOK262) FH-deficient cells7 (Extended Data Fig. 1). 44 
We found that vimentin, a known EMT marker, is the most overexpressed protein in these 45 
cells, compared to FH-proficient counterparts (Fig. 1a). Gene expression profiling (Fig. 1b) 46 
followed by Gene Set Enrichment Analysis (GSEA)8 confirmed an enrichment of EMT-related 47 
genes in FH-deficient cells (Extended Data Fig. 2 and Extended Data Fig. 3a, respectively). 48 
The reintroduction of full-length Fh1 (pFh1) in Fh1-/- cells (Extended Data Fig. 1a-e) was 49 
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sufficient to rescue the EMT signature (Extended Data Fig. 2a and Extended Data Fig. 2c), to 50 
abolish vimentin expression (Fig. 1c-e), and to restore expression of E-Cadherin (Fig. 1c-d), a 51 
key epithelial marker. Fh1-/-+pFh1 cells acquired an epithelial morphology (Extended Data 52 
Fig. 1e) and their motility was reduced compared to that of Fh1-deficient cells (Fig. 1f-g). 53 
UOK262 cells exhibited a strong Vimentin expression (Extended Data Fig. 3b-d), and 54 
increased migration (Extended data Fig. 3e) compared to UOK262pFH. However, localisation 55 
of E-Cadherin at the plasma membrane was not observed in UOK262pFH (Extended Data Fig. 56 
3d).  57 
EMT is orchestrated by several transcription factors, including Twist, Snai1, Snai2, and 58 
Zeb1/2 (ref 9). Twist, which is activated by the Hypoxia-Inducible Factor HIF1 (ref 10), a key 59 
player in FH-deficient tumours11,
 was elevated in Fh1-deficient cells (Fig. 1h). The silencing 60 
of HIF1β, the constitutively expressed subunit of HIFs required for their transcriptional 61 
activity12, failed to reduce the expression of EMT markers (Extended Data Fig. 4a-b), 62 
suggesting that EMT in Fh1-deficient cells is likely HIF-independent. Snai2, Zeb1 and Zeb2 63 
were also induced in Fh1-deficient cells, and their expression was reverted by Fh1 re-64 
expression in these cells (Fig. 1h-i). Zeb2 expression was also decreased upon FH restoration 65 
in UOK262 cells (Extended Data Fig. 3f). Snai2 and Zeb1/2 are suppressed by antimetastatic 66 
miRNAs miR-200ba429 and the miR-200c141 (ref 6). miRNA profiling revealed that miR-200 67 
family members were among the most down-regulated miRNAs in Fh1-deficient cells (Fig. 68 
2a). Suppression of MIR-200 was also observed in UOK262 cells compared to the non-69 
transformed counterpart HK2 and partially restored by FH re-expression (Extended Data Fig. 70 
3g-h). qPCR confirmed the miRNA profiling results and showed that the reconstitution of Fh1 71 
in Fh1-deficient cells restored the expression levels of miR-200a and miR-200b and, in part, 72 
that of miR-200c and miR-141 (Fig. 2b). We hypothesised that the partial restoration of miR-73 
200c141 could be ascribed to the residual fumarate in Fh1-/-+pFh1 cells (Extended Data Fig. 74 
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1c and Extended Data Fig. 5b), which could also explain the partial recovery of the EMT gene 75 
signature (Extended Data Fig. 2a-c). Blunting fumarate levels by re-expressing high levels of 76 
Fh1 in Fh1-/- cells rescued their phenotype (Extended Data Fig. 5b-g) and led to a full 77 
reactivation of the entire miR-200 family (Extended Data Fig. 5h), indicating that members of 78 
this family have a different susceptibility to fumarate. The incomplete rescue of fumarate levels 79 
in UOK262pFH (ref 7) could also explain the partial restoration of MIRNAs and some EMT 80 
markers in these cells.  81 
Since miR-200ba429 expression was fully restored in Fh1-/-+pFh1 and its expression 82 
was sufficient to suppress vimentin and rescue E-cadherin expression in Fh1-deficient cells 83 
(Fig. 2c), we investigated the role of this miRNA cluster in Fh1-dependent EMT. Repression 84 
of miR-200 is associated with its epigenetic silencing via CpG island hypermethylation13, 85 
which can also be caused by downregulation of Tets14,15. We hypothesised that fumarate could 86 
cause suppression of miR-200ba429 by inhibiting their Tets-mediated demethylation. The 87 
combined silencing of Tet2 and Tet3, the most abundant Tets isoform in Fh1fl/fl cells (Extended 88 
Data Fig. 6a), but not the inhibition of aKG-dependent histone demethylases with GSK-J4 (ref 89 
16), decreased miRNAs and E-Cadherin expression (Extended Data Fig. 6b-e), highlighting 90 
the role of Tets in regulating EMT, in line with previous findings14,15. Genome Browser17 view 91 
of an ENCODE dataset generated in mouse kidney cells revealed a conserved CpG island at 92 
the 5’ end of miR-200ba429, CpG43, that is enriched in binding sites for Tets and for lysine-93 
methylated histone H3 (Extended Data Fig. 7a). Chromatin immunoprecipitation (ChIP) 94 
experiments showed that a region adjacent to CpG43 is enriched for the repressive marks 95 
H3K9me2 and H3K27me3 and depleted of the permissive marks H3K4me3 and H3K27Ac in 96 
Fh1-deficient cells (Extended Data Fig. 7b) in the absence of changes in H3K4 and H3K27 97 
methylation among the four cell lines (Extended data Fig. 7c). Chromosome Conformation 98 
Capture (3C) analysis18 identified a physical association between this regulatory region and the 99 
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transcription starting site of miR-200ba429, which sits in the intronic region of the gene Ttl10 100 
(Extended Data Fig. 7d). This region was hypermethylated in Fh1-deficient cells and the re-101 
expression of Fh1 restored its methylation levels (Fig. 2d and Extended Data Fig. 7e). Binding 102 
of Tets to the CpG43 was comparable among the cell line tested (Extended Data Fig. 7f), 103 
suggesting that the changes in methylation of this region are, at least in part, caused by 104 
inhibition of Tets enzymatic activity rather than by their differential binding to chromatin. 105 
Consistently, 5-hydroxymethylcytosine (5hmc), the product of oxidation of 5-methylcytosine 106 
by Tets15, was significantly decreased in Fh1-deficient cells (Extended Data Fig. 7g).  107 
Incubating cells with dimethyl aKG (DM-aKG), a cell-permeable derivative of aKG, 108 
known to reactivate aKG-dependent dioxygenases19, restored the expression miR-200a in Fh1-109 
deficient cells (Extended Data Fig. 6f). Conversely, treating Fh1fl/fl and human FH-proficient 110 
epithelial kidney cells HK2 with monomethyl fumarate (MMF), a cell permeable derivative of 111 
fumarate triggered profound phenotypical (Extended Data Fig. 8a) and (epi)genetic (Fig. 3a-g) 112 
changes that resembled those of FH-deficient cells. However, we could not observe induction 113 
of Snai2 that we observed in Fh1-/- cells (Fig. 1h) and changes in Vimentin in HK2 cells, which 114 
is expressed in these cells22, despite their epithelial origin. MMF did not cause mitochondrial 115 
dysfunction but lead to a typical fumarate-dependent metabolic signature, characterised in both 116 
cell types by accumulation of fumarate and fumarate-derived succinic-GSH (succGSH) and 117 
succinic-cysteine (2SC) that we and others recently described20,21 (Extended Data Fig. 8b-c and 118 
SI Table 3). To rule out the possibility that by-products of fumarate accumulation, rather than 119 
fumarate itself, elicit EMT we analysed the effects of accumulation of succinate, another 120 
metabolite that can inhibit Tets3-5, but cannot promote succination. Since we could not increase 121 
succinate levels with the cell permeable dimethyl succinate (Extended Data Fig. 9a) we used 122 
succinate dehydrogenase b (Sdhb)-deficient cell lines23, which accumulate succinate but not 123 
fumarate by-products, including succGSH (Extended Data Fig. 9b-c). These cells exhibited 124 
Page 6 of 29 
striking mesenchymal features (Extended Data Fig. 9d-e), and epigenetic suppression of the 125 
miR-200ba429 family (Extended Data Fig. 9f-g), in line with the hypermethylation phenotype 126 
and EMT signature recently observed in SDH-deficient cells24.  127 
We next investigated the link between FH loss, fumarate accumulation and EMT in 128 
renal cancer samples. Vimentin was highly expressed and E-Cadherin was decreased in a 129 
previously published dataset25 of HLRCC tumour samples, when compared to normal tissue 130 
(Extended Data Fig. 10a). Two HLRCC tumours that we profiled (Fig. 4a), exhibited decreased 131 
5hmC levels (Fig. 4b) despite comparable TETs levels (Extended Data Fig. 10b), MIR-200 132 
suppression (Fig. 4c), a marked Vimentin staining and loss of E-Cadherin (Extended Data Fig 133 
10b), compared to matched normal tissue. We also took advantage of data from a collection of 134 
papillary renal-cell carcinoma (KIRP), a tumour type associated with loss of FH26. These 135 
tumours exhibited a partial EMT signature (Extended Data Fig. 10c) and downregulation of 136 
MIR-200 (Extended Data Fig. 10d). FH levels were positively correlated with patients’ survival 137 
(Extended Data Fig. 10e) in line with the poor prognosis associated with EMT6. The five FH-138 
mutant tumours in this cohort exhibited overexpression of Vimentin and suppression of E-139 
Cadherin (Extended Data Fig. 10f), hypermethylation and suppression of MIR-200A and MIR-140 
200B (Fig. 4d-e) in the absence of TETs mutations (Extended Data Fig. 10g). These tumours 141 
were associated with the worst prognosis among papillary cancers (Extended Data Fig. 10h). 142 
FH mRNA was also significantly decreased in a panel of clear cell renal carcinoma (KIRC)27 143 
(Extended Data Fig. 10i) and its levels negatively correlated with Vimentin (Pearson correlation 144 
coefficient of -0.5, p-value < 1e-5; Fig. 4f) and positively with E-Cadherin (Pearson correlation 145 
coefficient of 0.22, p-value < 1e-5; Fig. 4g), and were positively correlated with patients’ 146 
survival (Extended Data Fig. 10k), confirming the role of FH in tumour malignancy and patient 147 
outcome.  148 
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Our results report a novel link between the loss of FH and epigenetic suppression of 149 
miR-200 mediated by fumarate (see Extended Data Fig. 1f for a schematic). Although other 150 
mechanisms could contribute to fumarate-driven EMT, our findings offer an explanation for 151 
the suppression of MIR-200 in papillary and clear-cell renal carcinoma and the expression of 152 
EMT-related transcription factors, including ZEB2, in KIRC28. Our data imply that 153 
dysregulation of FH activity and fumarate accumulation have roles in EMT induction and may 154 
feature in other tumour types where FH loss has been reported, including neuroblastoma29, 155 
colorectal and lung cancer30.  156 
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Figure Legends 283 
Figure 1. FH-deficient cells display mesenchymal features. a, b, Volcano plots of 284 
proteomics (a) and RNA-seq (b) experiments. FDR = false discovery rate. c, d, mRNA 285 
expression measured by qPCR (c) and protein levels measured by western blot (d) of EMT 286 
markers. e, Immunofluorescence staining for vimentin and E-cadherin. Scale Bar = 25 µm. f, 287 
Cells migration assay. Data indicate cell index at 17 hours. Results were obtained from 4 (Fh1 288 
-/-+pFh1) or 3 replicate wells and presented as mean ± S.D. p-value was calculated using One 289 
way-ANOVA. g, Average speed of cells. p-value was calculated using Mann-Whitney test. 290 
Results were obtained from 3 independent cultures. h, mRNA expression of EMT-related 291 
transcription factors measured by qPCR. i, Western blot analysis of Zeb1. Calnexin was used 292 
as loading control. All qPCR results were obtained from 3 independent cultures and presented 293 
as RQ with max values, normalised for β-actin. p-values was calculated using unpaired t-test. 294 
*P ≤0.05, **P ≤0.01, ***P ≤0.001, ****P≤0.0001. For western blot source data, see 295 
Supplementary Figure 1. For Raw data see SI Table 2. 296 
Figure 2. Loss of Fh1 triggers epigenetic suppression of miR-200. a, Volcano plot of 297 
miRNA profiling. b, miRNAs expression measured by qPCR. Date were normalised to 298 
Snord95. c, miRNAs and EMT markers expression in Fh1-/- cells expressing miR-200ba429. 299 
β-actin and Snord95 were used as endogenous control for mRNA and miRNA, respectively. 300 
NTC= non-targeting control. d, Methylation-specific PCR of CpG43. U = un-methylated; M = 301 
methylated CpG island. The miR-200ba429 cluster (blue) and CpG43 (green) are represented 302 
in the schematic. qPCR results were obtained from at least 3 independent cultures and presented 303 
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as RQ with max values. p-values was calculated using unpaired t-test. *P ≤0.05, **P ≤0.01, 304 
***P ≤0.001, ****P≤0.0001. For gel source data, see Supplementary Figure 1. For Raw data 305 
see SI Table 2. 306 
Figure 3. Fumarate triggers EMT in FH-proficient cells. miRNA methylation (a) and 307 
expression (b, e); EMT transcription factors (c, f) and EMT markers (d, g) levels from MMF-308 
treated cells. Results were obtained from 3 independent cultures. qPCRs are presented as RQ 309 
with max values, normalised for Snord95 (mouse) or SNORD95 (human) for miRNAs, and for 310 
β-actin for mRNA. p-values were calculated using unpaired t-test. *P ≤0.05, **P ≤0.01, ***P 311 
≤0.001, ****P≤0.0001. For gel source data, see Supplementary Figure 1. For Raw data see SI 312 
Table 2. 313 
Figure 4. Loss of FH correlates with EMT signature in renal cancers. a-c, Metabolomic 314 
analysis (a), 5hmc levels in DNA (b), and MIRNAs expression (c) in tumour samples from 315 
two HLRCC patients. Results were obtained from 4 technical replicates per sample. qPCRs are 316 
presented as RQ with max values, normalised for RNU6B and SNORD61. d, e, Expression 317 
levels (d), and promoter methylation (e) of the indicated MIRNAs in KIRP patients f, g, 318 
Vimentin (f) and E-Cadherin (g) expression in clear cell renal cell carcinoma (KIRC) patients. 319 
For Raw data see SI Table 2. 320 
METHODS 321 
No statistical methods were used to predetermine sample size.  322 
Cell culture 323 
Fh1-proficient (Fh1fl/fl), and the two Fh1-deficient clones (Fh1-/-CL1, and Fh1-/-CL19 ) cells were 324 
obtained as previously described7. Fh1-/-+pFh1 were single clones generated from Fh1-/-CL19 325 
after stable expression of a plasmid carrying mouse wild-type Fh1 gene (Origene, MC200586). 326 
Mouse cells were cultured using DMEM (Gibco-41966-029) supplemented with 10% heat 327 
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inactivated serum (Gibco-10270-106) and 50 µg x mL-1 uridine. Genotyping of cells was 328 
assessed as previously described7. Human FH-deficient (UOK262) and FH-restored 329 
(UOK262pFH) were obtained as previously described7 and cultured in DMEM (Gibco-41966-330 
029) supplemented with 10% serum heat inactivated (Gibco-10270-106). HK2 cells were a gift 331 
from the laboratory of E.R.M. These cells were authenticated by Short Tandem Repeat and 332 
cultured in DMEM (Gibco-41966-029) supplemented with heat inactivated 10% serum. All 333 
cell lines have been tested for mycoplasma contamination using MycoProbe® Mycoplasma 334 
Detection Kit (R&D Systems CUL001B), and were confirmed mycoplasma-free. 335 
Generation of Fh1-/-+pFh1-GFP cells 336 
Fh1-GFP vector was generated by amplifying wild-type Fh1 sequence using cDNA generated 337 
from Fh1fl/fl cells by PCR. Restriction overhangs (KpnI, EcoRI) were included in the primer 338 
sequence allowing for restriction enzyme cloning of Fh1 into the backbone vector pEF1α-339 
V5/His (Life Technology). We then used a two-step PCR “restriction-free” method to swap the 340 
V5-His sequence within pEF1α with the AcGFP sequence to yield a fusion protein, Fh1-GFP. 341 
1x105 Fh1-/- CL1 cells were plated onto 6-well plate and the day after transfected with Fh1-GFP 342 
vector using Lipofectamine 2000 following manufacturer’s instructions. After 2 weeks, cells 343 
were sorted for GFP expression and the medium-expressing population was maintained in 344 
culture and amplified. pEF1α-GFP empty vector was used as control. Primers for cloning are 345 
listed in SI Table 1. 346 
Short hairpin RNA (shRNA) interference experiments 347 
Lentiviral particles for shRNA delivery was obtained as previously described7 from the filtered 348 
growth media of 2x106 HEK293T transfected with 3 µg psPAX, 1 µg pVSVG and 4 µg of the 349 
plasmid of interest using Lipofectamine 2000/3000 (Life Technology). 1x105 cells of the 350 
indicated genotype were then plated onto 6-well plates and infected with the viral supernatant 351 
in the presence of 4 µg x mL-1 polybrene. After two days, the medium was replaced with 352 
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selection medium containing 1 µg x mL-1 puromycin. pGIPZ vectors for shRNA against mouse 353 
HIF1β (RMM4532-EG11863), Tet2 (RMM4532-EG214133), and Tet3 (RMM4532-354 
EG194388) were purchased from GE Healthcare UK. pLenti 4.1 Ex for expression of 355 
microRNAs was purchased from Addgene (Plasmid #35533 and #35534). pLenti 4.1 Ex 356 
scrambled vector was generated cloning a scrambled DNA sequence taken from a 357 
commercially available vector (pCAG-RFP-miR-Scrint Addgene no. 198252) into the empty 358 
backbone.  359 
RNA extraction and real time PCR 360 
Cells were plated the day before the experiments onto 6-well plates (3x105) or 12-well plates 361 
(1x105). Total RNA was isolated using RNeasy Kit (Qiagen). miRCURY™ RNA Isolation Kit 362 
(Exiqon, Denmark) was used for microRNAs extraction. RNA isolation was carried following 363 
manufacturer’s protocols. RNA was quantified using the fluorimeter Qubit 2.0 (Life 364 
Technologies) following manufacturer’s instructions or Nanodrop (Thermo). Reverse 365 
transcription of RNA was performed using Quantitect-Reverse transcription kit (Qiagen) or 366 
miScript PCR kit (Qiagen) using 300-500 ng of total RNA. Real time qPCR was performed 367 
using Quantitect Syber Green master mix (Qiagen) or Taqman universal mix (Life Technology) 368 
on a Step One Plus real-time PCR system (Life Technology). Experiments were analysed using 369 
the software Expression Suite (Life Technology) and StepOne software 2.3 and Relative 370 
quantification (RQ) with max and min values (RQ max and RQ min) were calculated using 371 
S.D. algorithm. Statistical analysis was performed using Expression Suite software on at least 372 
three independent cultures. Housekeeping genes used for internal normalisation are β-Actin for 373 
mRNA and Snord95 Snord61 and RNU6B, for miRNAs. The primers were designed using 374 
ProbeFinder- Roche or purchased by Qiagen and are listed in SI Table 1. 375 
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miRNA methylation analyses  376 
5x105 cells were plated onto 6-cm dishes. Their genomic DNA was extracted using DNeasy kit 377 
(Qiagen), and purified using DNA Cleaning and Concentrator kit (Zymo Research) following 378 
manufacturer’s instructions. 20 ng/well of genomic DNA, quantified using Qubit, were 379 
digested using OneStep qMethyl kit (Zymo Research) following manufacturer’s protocol. 380 
Primers used are listed in the SI Table 1. 381 
For methyl specific PCR (MSP) assay 500 ng of purified DNA were bisulphate converted using 382 
the EZ-DNA Methylation-direct kit (Zymo Research) following manufacturer’s datasheet. 50 383 
ng of bisulphate-converted DNA, quantified using Nanodrop spectrofluorimeter, were used for 384 
PCR reaction with AmpliTaq Gold (Life Technology) following manufacturer’s protocol. The 385 
number of amplification cycles used was thirty. Methylation specific primers were designed 386 
using MethPrimer31 (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) and are 387 
listed in the SI Table 1.  388 
Migration assay  389 
Migration experiments were performed using xCELLigence instrument (ACEA Biosciences). 390 
In brief, 5x104 cells were plated onto CIM plates in medium supplemented with 1% FBS. 391 
Complete medium with 20% FBS was used as chemo attractant. Migration was registered in 392 
real time for at least 24 hours and cell index was calculated using the appropriate function of 393 
the xCELLigence software. 394 
Motility assay 395 
5x104 mouse cells of the indicated genotype were plated the day before the experiment onto 6-396 
cm dishes. The day after, medium was replaced with fresh medium containing Hoechst (Sigma-397 
Aldrich) and cells were incubated for 15 minutes at 37°C with 5% CO2 before starting 398 
recording. Images were collected every minute for 3 hours using a Zeiss Axiovert 200M 399 
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microscope with a 10x objective. Analysis of cells movement was performed using cell tracker 400 
(www.celltracker.website) implemented in MATLAB (MATLAB R2013b, The MathWorks 401 
Inc., 2013) as previously described32. Three replicates were analysed for each cell type. All 402 
tracks were examined and those belonging to non-isolated cells deleted. Average speed for 403 
each cell was calculated as the sum length of the cell’s trajectory divided by the total time over 404 
which the trajectory was measured. Since the data were not normally distributed (Shapiro-Wilk 405 
test), a Mann-Whitney test was used to compare the average speeds of the cells. 406 
Oxygen consumption rate and Extracellular acidification rate measurements  407 
Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) were 408 
measured using the real time flux analyser XF-24e (Seahorse Bioscience) as previously 409 
described7. In brief, 4x104 cells were left untreated and then treated with 1 µM Oligomycin, 2 410 
µM Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), Rotenone and Antimycin 411 
A (both 1 µM) (all purchased from Sigma-Aldrich). At the end of the run cells were lysed using 412 
RIPA buffer (25 mM Tris/HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 413 
0.1% SDS). Protein content for each well was measured using BCA kit (Pierce) following 414 
manufacturer’s instruction. OCR and ECAR are normalised to total protein content were 415 
indicated.  416 
Immunofluorescence experiments 417 
5x104 cells were plated onto chamber slides (Lab Tech), cultured in standard condition 418 
overnight and then fixed using 100% methanol for 2 minutes at –20°C. After two washes in 419 
PBS, cells were permeabilised and incubated with blocking solution (BSA 2%, 0.1% Triton X-420 
100, 0.1% Tween 20 in PBS) for 30 minutes at room temperature. Cells were then incubated 421 
with the primary antibody (overnight at 4°C). For 5hmc staining, cells were grown on 422 
coverslips onto a 12-well plate. Cells were then fixed with 4% PFA in PBS for 15 minutes at 423 
room temperature, washed three times in PBS and then incubated for 15 minutes with 0.4% 424 
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Triton X-100 in PBS. After three washes in PBS, cells were denaturated using a solution of 2 425 
M HCl for 15 minutes at room temperature and neutralised using 100 mM Tris pH.8, for 5 426 
minutes. After three washes in PBS, cells were incubated with blocking solution (5% FBS, 427 
0.1% Triton X-100, 0.1% Tween 20 in PBS) for 1 hour and then primary antibody was added 428 
at 4°C overnight. After three washes in PBS, cells were incubated with secondary antibody 429 
during 2 hours at room temperature and then slides or coverslips were mounted (Vectashield 430 
with DAPI) and images taken using Leica confocal microscope TCS SP5 using 20X or 40X 431 
objectives. Laser intensity, magnification, and microscope settings per each channel were 432 
maintained equal throughout the different experimental conditions. Antibodies used are listed 433 
in SI Table 1. 434 
Protein lysates and Western Blot 435 
Cell lysates were prepared in RIPA buffer. Protein content was measured using BCA kit 436 
(Pierce) following manufacturer’s instructions. 50-100 µg of proteins were heated at 70°C for 437 
10 minutes in presence of Bolt Loading Buffer 1x supplemented with 4% β-mercaptoethanol 438 
(Sigma). Samples were then loaded onto Bolt Gel 4-12% Bis-Tris (Life Technology) and run 439 
using MOPS 1x or MES 1x buffer at 165 V constant for 40 minutes. Dry transfer of the gels 440 
was carried using IBLOT2 system (Life Technology). Membranes were then incubated in 441 
blocking buffer (5% BSA or 5% milk in TBS 1x + 0.01 % Tween 20) for one hour at room 442 
temperature. Primary antibodies in blocking buffer were incubated overnight at 4°C. Secondary 443 
antibodies (conjugated with 680 or 800 nm fluorophores from Li-Cor) were diluted 1:2000 in 444 
blocking buffer and incubated for one hour at room temperature. Images were acquired using 445 
Odyssey software (Li-Cor). Primary antibodies are listed in SI Table 1. 446 
Chronic treatment of mouse and human cells 447 
Fh1fl/fl cells were cultured either with 200 µM monomethyl-fumarate (MMF, Sigma-Aldrich) 448 
for 2 weeks and then with 400 µM MMF for the following 6 weeks, or with 4 mM monomethyl-449 
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succinate (MMS, Sigma-Aldrich) for 8 weeks. HK2 cells were cultured with MMF 400 µM for 450 
8 weeks. Fh1-/- cells were treated with the indicated doses of dimethyl aKG (DM-aKG, Sigma-451 
Aldrich). Fh1 fl/fl cells were treated with histone demethylase inhibitor GSKJ4 (Tocris) 1 µM 452 
for 8 weeks. MMF, MMS and GSKJ4 were added twice a week after passaging the cells. 453 
Chromatin immunoprecipitation (ChIP)-real time PCR (ChIP-PCR) 454 
ChIP was performed as previously described33. Enrichment was determined by Real-time PCR 455 
and ChIP signal was normalised to input, IgG only ChIP and negative control (genomic region 456 
devoid of histone markers). For Tets ChIP-PCR, the signal was normalised over input and IgG 457 
ChIP, as Tet-specific genomic negative controls are not as readily identifiable. Antibodies and 458 
primers for ChIP-PCR are indicated in SI Table 1. 459 
Chromatin Conformation Capture assay (3C) 460 
3C assay coupled with quantitative PCR (qPCR) was performed as previously described18. In 461 
brief, 107 cells were crosslinked with 1% formaldehyde for 10 minutes at room temperature 462 
and were quenched with glycine. Cells were then lysed by dounce homogenization in ice-cold 463 
lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% Igepal CA-630, all from Sigma) 464 
supplemented with protease inhibitor (Roche). Cells were then washed in 1.2x NEB buffer 2 465 
(New England Biolabs). Non-crosslinked proteins were removed with SDS (Sigma- Aldrich) 466 
and were then quenched with Triton X-100. Chromatin was digested overnight with EcoR I 467 
restriction enzyme (New England Biolabs). Afterwards EcoR I was inactivated by heating at 468 
65˚C for 20 minutes. In-nuclear DNA ligation was performed at 16˚C for 4 hours in the mixture 469 
containing 1x T4 DNA ligase buffer (New England Biolabs), 10 mg/ml BSA (New England 470 
Biolabs), and 1U/μL T4 DNA ligase (Invitrogen). Ligation mixture was then incubated with 471 
Proteinase K (Roche) at 65˚C overnight to reverse the crosslinking and was incubated with 472 
RNase A (Roche) at 37˚C for 1 hour. DNA was purified with Phenol (pH 8.0, Sigma) once and 473 
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then with Phenol:Chloroform:Isoamyl Alcohol (25:24:1, pH 8.0, Sigma), followed by ethanol 474 
precipitation by adding 2.5 volume of ice-cold 100% ethanol and 1/10 volume of 3 M sodium 475 
acetate (pH 5.2, Lonza). DNA pellet was washed with 70% ethanol twice and was eventually 476 
dissolved in 100 μL distilled water. The concentration of 3C DNA was determined by Qubit 477 
dsDNA HS assays (Invitrogen). 100 ng DNA was taken to run qPCR in duplicate wells for 478 
each 3C sample, using Taqman Universal PCR Master Mix (Applied Biosystems) and specific 479 
Taqman primers and probes on ABI 7900 (Applied Biosystems) following manufacturer’s 480 
instruction. Data were analysed as recommended18 and were normalized to the internal loading 481 
control of Gapdh locus. Calculation of primers location was based on the transcription start 482 
site (TSS) of Ttll10 transcript (ENSMUST00000097731). Oligo sequences are listed in the SI 483 
Table 1.  484 
Metabolomic analyses 485 
3x105 cells were plated onto a 6-well plate and cultured in standard conditions for 24 hours. 486 
Medium was replenished with fresh one and, after 24 hours, intracellular metabolites were 487 
extracted as previously described20. LCMS analysis was performed on a QExactive Orbitrap 488 
mass spectrometer coupled to Dionex UltiMate 3000 Rapid Separation LC system (Thermo). 489 
The liquid chromatography system was fitted with either a SeQuant Zic-HILIC column 490 
(column A, 150 mm × 4.6 mm, internal diameter 3.5 µm), or a SeQuant Zic-pHilic (column B, 491 
150 mm × 2.1 mm, internal diameter 3.5 µm) with guard columns (20 mm × 2.1 mm, internal 492 
diameter 3.5 µm) both from Merck (Darmstadt, Germany). With column A, the mobile phase 493 
was composed by 0.1% aqueous formic acid (solvent A) and 0.1% formic acid in acetonitrile 494 
(solvent B). The flow rate was set at 300 μL x min-1 and the gradient was as follows: 0-5 min 495 
80 % B, 5-15 min 15 min 30% B, 15-20 min 10 % B, 20-21 min 80% B, hold at 80% B for 9 496 
minutes. For column B, the mobile phase was composed of 20 mM ammonium carbonate and 497 
0.1% ammonium hydroxide in water (solvent C), and acetonitrile (solvent D). The flow rate 498 
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was set at 180 µL x min-1 with the following gradient: 0 min 70% D, 1 min 70% D, 16 min 499 
38% D, 16.5 min 70% D, hold at 70% D for 8.5 minutes. The mass spectrometer was operated 500 
in full MS and polarity switching mode. Samples were randomised, in order to avoid machine 501 
drift, and were blinded to the operator. The acquired spectra were analysed using XCalibur 502 
Qual Browser and XCalibur Quan Browser softwares (Thermo Scientific) by referencing to an 503 
internal library of compounds. Calibration curves were generated using synthetic standards of 504 
the indicated metabolites. 505 
Proteomics analysis  506 
Proteomics experiments were performed using mass spectrometry as reported before34,35. In 507 
brief, cells were lysed in urea lysis buffer (8 M urea, 10 mM Na3VO4, 100 mM β-Glycerol 508 
phosphate and 25 mM Na2H2P2O7 and supplemented with phosphatases inhibitors-Sigma) and 509 
proteins reduced and alkylated by sequential addition of 1 mM DTT and 5 mM iodoacetamide. 510 
Immobilised trypsin was then added to digest proteins into peptides. After overnight incubation 511 
with trypsin, peptides were desalted by solid phase extraction (SPE) using OASIS HLB 512 
columns (Waters) in a vacuum manifold following manufacturer’s guidelines with the 513 
exception that the elution buffer contained 1 M glycolic acid.  514 
Dried peptide extracts were dissolved in 0.1% TFA and analysed by nanoflow LCMS/MS in 515 
an LTQ-orbitrap as described before34,35. Gradient elution was from 2% to 35% buffer B in 90 516 
minutes with buffer A being used to balance the mobile phase (buffer A was 0.1% formic acid 517 
in water and B was 0.1% formic acid in acetonitrile). MS/MS was acquired in multistage 518 
acquisition mode. MS raw files were converted into Mascot Generic Format using Mascot 519 
Distiller (version 1.2) and searched against the SwissProt database (version 2013.03) restricted 520 
to human entries using the Mascot search engine (version 2.38). Allowed mass windows were 521 
10 ppm and 600 mmu for parent and fragment mass to charge values, respectively. Variable 522 
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modifications included in searches were oxidation of methionine, pyro-glu (N-term) and 523 
phosphorylation of serine, threonine and tyrosine. Results were filtered to include those with a 524 
potential for false discovery rate less than 1% by comparing with searches against decoy 525 
databases. Quantification was performed by obtaining peak areas of extracted ion 526 
chromatographs (XICs) for the first three isotopes of each peptide ion using Pescal 36,37. To 527 
account for potential shifts in retention times, these were re-calculated for each peptide in each 528 
LCMS/MS run individually using linear regression based on common ions across runs (a script 529 
written in python 2.7 was used for this retention time alignment step). Mass and retention time 530 
windows of XICs were 7 ppm and 1.5 minutes, respectively.  531 
Toray miRNA array 532 
Initial sample quality control was performed using a Bioanalyzer 2200 system in conjunction 533 
with the Total RNA Nano chip (Agilent, Cheadle UK). 250 ng total RNA were labelled using 534 
the miRCURY LNA microRNA Hy5 Power labelling kit (Exiqon, Vedbæk Denmark) 535 
according to the Toray array protocol. Samples were hybridized to the Human/Mouse/Rat 536 
miRNA 4-plex miRBase v17 array (Toray, London UK) and subsequently scanned using the 537 
3D-Gene Scanner 3000 (Toray) according the manufacturer’s instructions. Data was 538 
normalized according to instructions provided by Toray. Briefly, presence or absence of signals 539 
was determined using a cut off defined as the mean of the middle 90% of the blank control 540 
intensities (background average intensity) + 2σ. Positive control signals were removed and the 541 
background average intensity subtracted from the signal intensities to give the background 542 
subtracted signal intensities (y). Normalised signal intensities (NSI) were then calculated as 543 
follows: NSI = 25𝑦/(𝑦). Raw data are presented in SI Table 4. 544 
Mass spectrometry-based analysis of methylated DNA of HLRCC tumours 545 
DNA from healthy and tumour tissue was extracted using DNeasyKit (Qiagen) following 546 
manufacturer’s instructions. 0.5-1 µg of DNA resuspended in 25 µL of water was first 547 
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denatured at 100°C for 30 seconds, cooled on ice, and then added of 2 µL of 20 mM ZnSO4. 548 
DNA was digested at 50°C for 16 hours using 1 µL Nuclease P1 (200 units x mL-1, Sigma 549 
Aldrich) and dephosphorylated at 65°C for 2 hours by adding 1 µL of Bacterial alkaline 550 
phosphatase BAP (150 U x µL-1, Life Technology). pH was then adjusted using 30 µL of 0.5 551 
M Tris-HCl pH 7.9 for one hour at 37°C.  552 
Analysis of global levels of C, 5hmC and 5mC was performed on a QExactive Orbitrap mass 553 
spectrometer coupled to a Dionex UltiMate 3000 Rapid Separation LC fitted with an Acquity 554 
UHPLC HSS T3 column (100 x 2.1 mm, 1.8 µm particle size). The mobile phase consisted of 555 
0.1% aqueous formic acid (solvent A) and 0.1% formic acid in acetonitrile (solvent B) at a flow 556 
rate of 300 µl x min-1. Calibration curves were generated using synthetic standards for 2’-557 
deoxycytidine, 5-methyl- and 5-hydroxymethyl-2’-deoxycytidine (Berry&Associates). The 558 
mass spectrometer was set in a positive ion mode and operated in parallel reaction monitoring. 559 
Ions of masses 228.10, 242.11, and 258.11 were fragmented and full scans were acquired for 560 
the base fragments 112.0505, 126.0661, and 146.0611 ± 5ppm (corresponding to C, 5mC and 561 
5hmC, respectively). The extracted ion chromatogram (EIC) of the corresponding base-562 
fragment was extracted using the XCalibur Qual Browser and XCalibur Quan Browser 563 
software (Thermo Scientific), and used for quantification. Quantification was performed by 564 
comparison with the standard curve obtained from the pure nucleoside standards running with 565 
the same batch of samples. The level of 5hmC present in the sample was expressed as a 566 
percentage of total cytosine content. 567 
Immunohistochemistry on HLRCC tumours 568 
Specimens were formalin fixed and embedded in paraffin wax; 3-μm serial sections mounted 569 
on Snowcoat X-tra slides (Surgipath, Richmond, IL) were dewaxed in xylene and rehydrated 570 
using graded ethanol washes. For antigen retrieval, sections were immersed in preheated 571 
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DAKO target retrieval solution (DAKO) and treated for 90 seconds in a pressure cooker. 572 
Sections analysed contained both tumour and adjacent normal renal parenchyma acting as an 573 
internal control; in addition, substitution of the primary antibody with antibody diluent was 574 
used as a negative control. Antigen/antibody complexes were detected using the Envision 575 
system (DAKO) according to the manufacturer's instructions. Sections were counterstained 576 
with hematoxylin for 30 seconds, dehydrated in graded ethanol washes, and mounted in DPX 577 
(Lamb, London, United Kingdom). Antibodies used were: E-cadherin (HECD1, CRUK) and 578 
vimentin (clone V9, Dako). TET1 (SAB 2501479) and TET2 (HPA 019032) antibodies were 579 
purchased by Sigma Aldrich. 580 
miRNA expression on HLRCC tumours 581 
Total RNA was extracted from tumour and healthy tissue using miRCURY kit (Exiqon, 582 
Denmark) following manufacture’s protocols. RNA reverse-transcription and real-time qPCR 583 
were obtained as described above. Data are normalised to healthy tissue using both SNORD61 584 
and RNU6B as endogenous controls. 585 
Clinical details of HLRCC patients 586 
The patients consented to use of tissues for study approved by the National Research Ethics 587 
Committee London (REF number 2002/6486 and 03/018). FH mutations in HLRCC Patient A 588 
is c.1300T>C, and in Patient B is c.1189G>A  589 
Bioinformatics and statistical analyses 590 
Volcano plots were generated using the log10 fold-change on the x-axis and the -log10 of the 591 
multi hypothesis corrected p-value (false-discovery rate) on the y-axis generated by Limma38 592 
differential analysis. The Epithelial–Mesenchymal Transition gene signature was extracted 593 
from Taube and colleagues39. Signature enrichment was performed with the commonly used 594 
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Gene-Set Enrichment Analysis (GSEA)8 test. Signature significance was calculated by 595 
randomizing the genes signatures 10000 times. 596 
The TCGA RNA-seq and miRNA-seq data-sets for clear cell (KIRC) and papillary (KIRP) 597 
renal carcinoma were downloaded from the Broad Firehose webpage 598 
(http://gdac.broadinstitute.org/). Differential analysis was performed with R package Limma38 599 
using voom40 to transform the RNA-seq counts. Cancer patients were ranked according to FH 600 
expression and survival analysis was performed by comparing the overall survival time of 601 
upper vs. lower quartile of the FH-ranked list of patients. Kaplan Meier curves were built using 602 
in-house R scripts and significance was calculated using the R package Survival by applying a 603 
χ2 test. Hive plots were generated using the R package “HiveR”.  604 
Graphpad Prism 6 was used to generate graphs and perform statistical analysis (one-way 605 
ANOVA test with Tukey’s post hoc test for multiple comparisons was used unless otherwise 606 
indicated). ChIP statistical analysis was generated using Excel (Microsoft). Except for 607 
metabolomic experiments, no randomization or blinding was performed. No statistical method 608 
or power analysis was used to predetermine sample size.  609 
Code availability 610 
The R and Python scripts for the analyses above can be found at 611 
http://www.ebi.ac.uk/~emanuel/Sciacovelli_et_al/.  612 
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Extended Data Figure Legends 640 
Extended Data Figure 1. Characterisation of Fh1-deficient and Fh1-rescued cells. a, PCR 641 
to assess Fh1 recombination. The putative genotypes are indicated on the right and are based 642 
on the expected size of the genomic PCR amplification products as from Frezza et al7. Fh1fl/fl 643 
= 470 bp and Fh1-/-= 380 bp. b, Fh1 protein levels measured by western blot of cells of the 644 
indicated genotype. Calnexin was used as loading control for western blot. c, Intracellular 645 
fumarate levels measured by LCMS and normalised to total ion count. Results were obtained 646 
from 4 independent cultures and are indicated as average ± S.D.. p-values were calculated from 647 
one-way ANOVA. d, Oxygen Consumption rate (OCR) and Extracellular Acidification rate 648 
(ECAR) assessed using the Seahorse Extracellular Flux Analyser. Results were obtained from 649 
5 replicate wells and are presented as average ± S.D.. e, Bright field images of cells of the 650 
indicated phenotype. Bar = 400 µm. Western blot and gel sources are presented in 651 
Supplementary Figure 1. Raw data are presented in SI Table 2. *P ≤0.05, **P ≤0.01, ***P 652 
≤0.001, ****P≤0.0001. f, Schematic representation of the proposed link between loss of FH, 653 
fumarate accumulation, and epigenetic suppression of the antimetastatic cluster of miRNA 654 
miR-200. Upon accumulation of fumarate as a result of FH inactivation, the TET-mediated 655 
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demethylation of the miR-200ba429 cluster is inhibited, leading to their epigenetic suppression. 656 
As a consequence, Zeb1/2 are de-repressed, eliciting a signalling cascade that leads to EMT. 657 
Extended Data Figure 2. EMT signature in Fh1-/- cells. a, Volcano plot of RNA-seq 658 
analysis. Gene expression was normalised to Fh1fl/fl or Fh1-/-+pFh1 cells as indicated. b, c, 659 
Gene set enrichment analysis (b) and EMT enrichment score (c) of the indicated cell lines.  660 
Extended Data Figure 3. EMT signature in UOK262 cells. a, Gene set enrichment analysis 661 
and EMT enrichment score of the indicated cell lines. Gene expression was normalised to 662 
UOK262pFH. b, c, mRNA expression measured by qPCR (b) and protein levels measured by 663 
western blot (c) of the indicated EMT markers. d, Immunofluorescence staining for Vimentin 664 
and E-Cadherin. DAPI was used as marker for cell nuclei. Scale Bar = 25 µm. e, Cell migration 665 
rate. Results were obtained from 14 replicate wells and presented as mean ± S.D.. f, mRNA 666 
expression of EMT-related transcription factors ZEB1 and ZEB2 from RNA-seq data as in Fig. 667 
1a. g, Expression levels of the indicated miRNAs measured by qPCR. h, Volcano plot of 668 
miRNA profiling. All qPCR experiments were obtained from 3 independent experiments and 669 
presented as RQ with max values, normalised to β-actin or RNU6B/SNORD61 as endogenous 670 
control for mRNA and miRNA analyses, respectively. *P ≤0.05, **P ≤0.01, ***P ≤0.001, 671 
****P≤0.0001. Western blot sources are presented in Supplementary Figure 1. Raw data are 672 
presented in SI Table 2. 673 
Extended Data Figure 4. EMT features in Fh1-deficient cells are independent from HIF. 674 
mRNA levels of EMT genes (a) and HIF target genes (b) in Fh1-/- cells infected with shRNA 675 
against HIF1β measured by qPCR. Results were obtained from 3 independent cultures and 676 
presented as RQ with max values using β-actin as endogenous control. NTC = non-targeting 677 
control. p-values from unpaired t-test are indicated in the graph. LdhA = lactate dehydrogenase 678 
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A; Pdk1 = pyruvate dehydrogenase kinase 1; Glut 1 = glucose transporter 1. *P ≤0.05, **P 679 
≤0.01, ***P ≤0.001, ****P≤0.0001. Raw data are presented in SI Table 2. 680 
Extended Data Figure 5. EMT signature in Fh1-reconstituted cells. a, Fh1 protein levels 681 
measured by western blot. Calnexin was used as loading control. b, Intracellular fumarate 682 
levels the measured by LCMS. Data are presented as average ± S.D.. c, Representative bright 683 
field images of cells of the indicated genotype. Scale Bar = 400 µm. d, e, mRNA expression 684 
measured by qPCR (d) and protein levels measured by western blot (e) of the indicated EMT 685 
markers. f, Average speed of cells calculated after tracking cells for 3 hours as in Fig. 1g. 686 
Results were generated from 3 independent cultures. g, mRNA expression of EMT-related 687 
transcription factors. β-actin was used as endogenous control. EV = empty vector. h, 688 
Expression levels of the indicated miRNAs measured by qPCR and normalised to Snord95 and 689 
Snord61 as endogenous control. All qPCR results were obtained from 3 independent cultures 690 
and presented as RQ with max values. *P ≤0.05, **P ≤0.01, ***P ≤0.001, ****P≤0.0001. 691 
Western blot sources are presented in Supplementary Figure 1. Raw data are presented in SI 692 
Table 2. 693 
Extended Data Fig. 6. Role of Tets and Histone Demethylases in EMT induction. a, 694 
Expression levels of Tet1-3 in Fh1 fl/fl from RNA-seq data. b, d, Expression levels of Tet2/3 695 
(b), miRNA200 (c), and E-cadherin (d) in Fh1 fl/fl cells upon combined silencing of Tet2 and 696 
Tet3. The results are presented as RQ with max values obtained from technical replicates. β-697 
actin and Snord61 were used as endogenous control for mRNA and miRNA, respectively. e, 698 
Expression levels of the indicated miRNAs upon inhibition of histone demethylases by GSK 699 
J4. Snord61 and Snord95 were used as endogenous controls. f, Expression of the indicated 700 
miRNAs in Fh1-/- cells incubated for 24 hours with 5 mM DM-aKG measured by qPCR. 701 
Results were obtained from 4 (vehicle) or 5 (Fh1-/-CL19) and 3 (Fh1-/-CL1) (DM-aKG) 702 
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independent cultures and presented as RQ with max values, normalised to Snord95 as 703 
endogenous control. *P ≤0.05, **P ≤0.01, ***P ≤0.001, ****P≤0.0001. 704 
Extended Data Fig. 7. Characterisation of the regulatory CpG island CpG43. a, Snapshot 705 
of Genome Browser view of genomic DNA around the miR200ba429 cluster taken from 706 
NCBI37/mm9. Tet2 ChIP was obtained from GSE41720, sample GSM1023124. Shaded 707 
rectangles indicate miR-200ba429 and CpG43. b, ChIP-PCR of the indicated histone marks in 708 
a region adjacent CpG43. Data were obtained from 3 independent cultures and are presented 709 
as average ± S.D.. p-values from unpaired t-tests are indicated in the graph. c, Expression levels 710 
of H3 histone marks in cells of the indicated genotypes measured by western blot. H3 used as 711 
loading control. d, 3C data of the genomic region adjacent to CpG43 analysed in Fh1fl/fl cells. 712 
The position of CpG30 and CpG43, and of the predicted restriction sites are indicated in the 713 
graph. Results were generated from 2 independent cultures. e, DNA methylation of the CpG43 714 
assessed by qPCR using OneStep qMethyl kit. Data were obtained from 3 independent 715 
experiments and normalised to methylation levels of the region in Fh1fl/fl. Data are presented 716 
as average ± S.E.M.. f, ChIP-PCR of Tets binding to CpG43. Data were obtained from three 717 
replicates and are presented as average ± S.D.. g, 5hmc nuclear staining assessed by 718 
immunofluorescence using 5hmc antibody. Nuclear staining was quantified using Image J and 719 
an average of 120 cells was used per genotype. p-values from One-way ANOVA test. 720 
Representative images of 5hmc staining are shown. DAPI is used to indicate the nuclei. Bar = 721 
20 μm. *P ≤0.05, **P ≤0.01, ***P ≤0.001, ****P≤0.0001. Western blot sources are presented 722 
in Supplementary Figure 1. Raw data are presented in SI Table 2. 723 
Extended Data Fig. 8. Monomethyl Fumarate (MMF) triggers EMT in FH-proficient 724 
cells. a, Bright field images of cells treated for 6 weeks with MMF. Arrows indicate the typical 725 
protrusion of cells of mesenchymal phenotype. Bar = 400 µm. b, Oxygen consumption rate of 726 
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the indicated cell lines treated chronically with MMF (as in Fig. 3). See Methods for drugs 727 
concentrations. OCR was normalised to total protein content. Results were obtained from 6 728 
(for mouse cells) or 8 (for human cells) wells ± SD.. c, Hive plot of metabolomics data of 729 
mouse and human cells treated with MMF (as in Fig. 3). All identified metabolites are included 730 
on the y-axis and grouped into human (pink) and mouse (green) cells. Metabolites accumulated 731 
(right x-axis) or depleted (left x-axis) in MMF-treated cells versus control are indicated by a 732 
connecting arc and their fold-change is colour-coded. Metabolites accumulated commonly 733 
across the two cell lines are highlighted with a solid line. 2SC: 2-succinic-cysteine, succGSH: 734 
succinic-GSH. Raw data are presented in SI Table 2. Raw metabolomic data are presented in 735 
SI Table 3. 736 
Extended Data Fig. 9. Succinate triggers EMT in Sdhb-deficient cells. a, Intracellular 737 
succinate levels after incubation with 4 mM MMS measured by LCMS. Data are presented as 738 
average ±S.D.. b, c, Intracellular succinate (b) and succGSH (c) levels in Sdhb-deficient cells 739 
measured by LMCS. Data are presented as average ±S.D.. d, Bright field images of cells of the 740 
indicated genotype. Bar = 400 µm. e, Gene set enrichment analysis and EMT enrichment score 741 
from expression analysis of the indicated cell lines. f, g, miRNA expression levels normalised 742 
to Snord61 and Snord95 as endogenous control (f) and CpG43 methylation (g). Experiments 743 
were performed as in Fig. 2b and 2d, respectively. *P ≤0.05, **P ≤0.01, ***P ≤0.001, 744 
****P≤0.0001. Gel sources are presented in Supplementary Figure 1. Raw data are presented 745 
in SI Table 2. 746 
Extended Data Fig. 10. Expression of FH and EMT markers in kidney cancer. a, 747 
Expression levels of Vimentin and E-Cadherin in HLRCC patients obtained from Ooi et al25. 748 
b, Immunohistochemistry staining of Vimentin and E-Cadherin (left), and TET1 and TET2 749 
(right) in HLRCC patients obtained as in Fig. 4a. Bar = 100 µm. The insert in the left panel 750 
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indicate a 3X digital magnification, Bar = 50 µm. c, Gene set enrichment analysis and EMT 751 
enrichment score from RNA-seq data of papillary renal cell carcinoma (KIRP) obtained by 752 
Linehan et al26. d, Volcano plot of MIRNA expression in KIRP. e, Kaplan-Meier curve of 753 
KIRP patients separated according to FH expression. f, Vimentin and E-Cadherin expression 754 
in FH-mutant KIRP compared to normal renal tissue. g, Frequency of mutations in FH and 755 
TET1, TET2 and TET3 in KIRP analysed using NCBO BioPortal. Only cancers with mutations 756 
in the indicated genes are shown. h, Kaplan-Meier curve of FH-wild type and FH-mutant KIRP. 757 
i, Expression levels of FH, Vimentin, and E-Cadherin in clear cell renal cell carcinoma (KIRC) 758 
obtained from TCGA dataset27. j, Volcano plot of miRNA expression in KIRC. j, Kaplan-759 
Meier curve of KIRC patients separated according to FH expression. 760 
